Our founders are building beyond the pre-defined edges of human health. Through the convergence of AI, technology, and biology, and the reimagining of healthcare, we’re the first call for bold entrepreneurs pushing boundaries and leading the way towards better care for all.
From life sciences to care delivery, spanning seed financing through IPO, we’re partnering with a new generation of determined, multidisciplinary entrepreneurs across the entire company‑building journey. Together we are building iconic companies that are radically transforming how we diagnose, treat, and manage disease, while building the healthcare system of tomorrow–a system of Enduring Health (™). Together, we are building the future. The Future is Health.
a16z leads Counsel Health’s $25M Series A, alongside GV, to redefine what it means to access healthcare.
If you're one of the ~80M Medicaid-eligible Americans, you've probably experienced major whiplash in recent years. From continuous enrollment changes during the COVID-19 public health emergency, state-by-state Medicaid e...
In this episode, Tennr cofounder and CEO Trey Holterman sits down with a16z’s David Haber and Jay Rughani to unpack one of healthcare’s most overlooked pain points: patient referral logistics. When a patient is referred...
What if one of healthcare’s most complex administrative challenges—revenue cycle management—was reframed as a data science problem? In this episode, Malinka Walaliyadde, co-founder and CEO of Akasa, joins Julie Yoo to un...
What if we stopped trying to cure disease and started preventing it instead? In this episode, Dr. Eric Topol joins general partner Vijay Pande, PhD, to unpack the future of aging, prevention, and precision health—as explored in Eric's new book, Super Agers: An Evidence-Based Approach to Longevity.
American healthcare is in crisis—but what if we could change the system by preventing disease before it starts?
Arif Nathoo, cofounder and CEO of Komodo Health, joins Jorge Conde and Jay Rughani to explore the transformative potential of healthcare data in reshaping biotech and healthcare innovation. Arif reflects on a decade-long...
Join a16z general partners Marc Andreessen, Julie Yoo, and Vijay Pande for an incisive exploration of what's driving—and stalling—transformation in healthcare. With the industry now consuming nearly 20% of U.S. GDP yet d...
Seth Hain, SVP of R&D at Epic, joins a16z Bio + Health general partner Julie Yoo to explore technology in healthcare. Reflecting on over two decades of industry shifts, Seth shares how Epic has transitioned from enab...
Elliot Cohen, cofounder of PillPack, joins Julie Yoo, a16z Bio + Health general partner. Together, they discuss Elliot's experience designing and building a consumer-first pharmacy alongside TJ Parker.
In this episode, Slingshot AI cofounders Daniel Cahn and Neil Parikh join a16z Bio + Health general partner Julie Yoo to explore how their mission to transform mental health care with AI took shape. Drawing from their un...
Dr. Muthu Alagappan, MD, founder and CEO of Counsel Health, joins Julie Yoo, a16z Bio + Health general partner, to dive deep into the company's vision for revolutionizing healthcare through AI-powered asynchronous care....
Ankit Jain, CEO and cofounder of Infinitus Systems, Inc, joins Julie Yoo, a16z Bio + Health general partner, to discuss Infinitus's work in solving one of healthcare's most pressing challenges: workforce shortages. Lever...
Alexander Saint-Amand, cofounder and CEO of Topography, reflects on his journey from leading Gerson Lehrman Group (GLG), a pioneer in expert networks, to tackling systemic barriers in clinical trials at his current compa...
In the “Maslow's hierarchy” of the healthcare industry’s needs, the infrastructure layer is the foundational workhorse of the system. Healthtech infrastructure refers to the utilities and systems-of-record that underpin all of the core operational transactions, financial transactions, data exchange, and interoperability actions that occur across the healthcare system everyday.
Healthcare is a $4 trillion industry, making up nearly a fifth of the U.S. economy—but despite having some of the best doctors and advanced technology, the system often delivers poor outcomes at skyrocketing costs. Why i...
Andreessen Horowitz (a16z) Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech Ecosystem Venture Fund (“Fund”) seeks to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients’ lives.
Today, we’re proud to announce we’ve led the Series A for Slingshot, the world’s first foundation model for psychology. This brings the total capital raised for the company to $40 million.
Rajaie Batniji, MD, PhD, Afia Asamoah, JD, and Sanjay Basu, MD, PhD, cofounders of Waymark, join Vineeta Agarwala, MD, PhD, a16z Bio + Health general partner, to discuss their transformative approach to Medicaid care delivery.
Hippocratic AI cofounder and CEO Munjal Shah joins a16z Bio + Health general partner Julie Yoo to explore the incredible potential of generative AI in transforming healthcare delivery.
Jeff Margolis, founder of TriZetto, joins Julie Yoo, a16z Bio + Health general partner, to share the journey of building an iconic company in healthcare infrastructure. From the early days of managed care to creating a t...
As we prepare to step into 2025, the possibilities for applied AI are reshaping industries in profound ways.
Matt Wilsey, cofounder and CEO of Grace Science, joins Jorge Conde, Bio + Health general partner, to share the profound personal story of his daughter Grace's diagnosis with NGLY1 deficiency and how it catalyzed his journey to founding a biotech startup aimed at developing a cure for his daughter’s condition.
An external "AI brain." Big swings in biopharma. Infinite games. A nuclear resurgence. "Faceless" creators. Google search challengers. Battlefield AI. We asked 50 a16z partners to preview one big idea that will spur innovation in 2025.
Carolyn Bertozzi, PhD, Director of Sarafan Stanford ChEM-H and professor at Stanford University, joins Jorge Conde, general partner at a16z Bio + Health.
What if the biggest challenge of our time isn’t living longer, but living better?
In this episode, a16z partners Jorge Conde and Jay Rughani sit down with Sajith Wickramasekara, CEO and cofounder of Benchling, to unpack the evolution of Benchling from idea to transformative software platform.
Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.
Jonathan Lim, chairman and CEO of Erasca, joins Jorge Conde, general partner at a16z. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making.
Today, we are thrilled to announce our investment in Alchemy as they work to better connect our life sciences and healthcare delivery systems and solve these supply-demand mismatches in the pharmaceutical value chain. Alchemy has emerged to empower the long tail of independent providers with the physical, clinical, and digital infrastructure they need to fully serve their patient communities effectively, and profitably.
If these modalities have proven to be so effective (in some cases, even curative) against cancer, is there a role for them outside oncology, in the treatment of chronic diseases that might also be driven by a population of bad-actor cells? Arda Therapeutics is building upon exactly this bold hypothesis.
Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.
Marta Bralic Kerns, founder and CEO of Pomelo Care, joins Will Shrank, MD, a16z Bio + Health venture partner. Together, they talk about the innovator’s dilemma with building in the Medicaid space
Nikita Singareddy, cofounder and CEO of Fortuna Health, joins Will Shrank, MD, a16z Bio + Health venture partner. This is the second episode in our Medicaid Matters series.
GCTx is flipping the entire iPSC differentiation paradigm on its head. Rather than manually iterating through a limited set of differentiation protocols, the Human TFome technology platform instead deploys large-scale combinatorial screening to discover new hypotheses and new protocols that are as-yet unknown to even the best biologists.
Over the next three episodes, we’re going to talk about why Medicaid matters, and the potential for technology to make it easier for enrollees to access and utilize the program. Our first guest is Mark Smith, MD, Clinical Professor of Medicine at UCSF.
Ambience cofounder Nikhil Buduma discusses how to build vertical applications with AI models, including in health care, and why tech expertise isn't enough.
Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast.
Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande, PhD, founding partner of a16z Bio + Health.
Half of prescribed medications are never taken, and 88% of Americans are metabolically unhealthy. Despite spending 20% of our GDP on healthcare—twice that of any other developed nation—our outcomes still lag behind. In t...
Consumers are effectively a new class of payor. And a number of opportunities exist to build solutions for those consumers (aka these new “micro payors”) to fund, navigate, and manage their healthcare purchases.
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z. This is a follow-up to their 2023 episode, where they discussed how biopharma can adapt to AI.
Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, PhD, general partner at a16z Bio + Health.
Whereas we historically have viewed the low adoption of software as a liability, we now view that as an asset—we don't face the same sunk cost bias that might be slowing other industries down from taking full advantage of the latest AI innovations.
Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.
Vijay Pande walks us through two decades of applying software engineering and AI to biotech and health care — from Folding@Home through AlphaFold and more.
Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.
In this episode, a follow-up to our episode Grand Challenges in Healthcare AI, Julie Yoo and Vijay Pande, a16z general partners, answer audience questions about AI applications in healthcare.
John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joins Jorge Conde, general partner at a16z Bio + Health.
Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health.
Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.
Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.
Recently, we invested in Function Health, a company that embodies the vision and excitement we had when writing those theses. The one piece we underestimated is the current state of latent demand among consumers for a new approach to healthcare and longevity.
This medical home is exactly what knownwell is building – and scaling. Through a hybrid virtual and in-person care model, knownwell offers both primary care as well as longitudinal specialty care, inclusive of weight management, diabetes care, medication (and side effect) management, multi-disciplinary nutritional counseling, and behavioral health services.
The most impactful way to fix healthcare is through improving the consumer experience, which has been largely ignored to date. In today’s modern world where you can order groceries, buy flight tickets, and wire money from your phone, taking care of yourself and navigating the healthcare system remains impossibly hard.
AI, science, and technology experts explore the real challenges and enormous opportunities facing entrepreneurs who are building the future of health. Raising Health dives deep into the heart of biotechnology and healthcare innovation. Join veteran company builders Vijay Pande, Julie Yoo, Vineeta Agarwala, and Jorge Conde, and co-hosts Kris Tatiossian and Olivia Webb, on this journey.
Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. Exits include current and former a16z portfolio companies which have been acquired as well as companies which have undergone an initial public offering or direct public offering of shares. Certain publicly traded companies on this list may still be held in Andreessen Horowitz funds. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/. Additionally investments that have participated in a16z accelerator programs can also be found here: https://speedrun.a16z.com/companies/. Excluded from this list are investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets. Further, the list of investments is updated monthly and as such may not reflect most recent a16z investments. Past results of Andreessen Horowitz’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results.
Catalysts. Conveners. Connective Tissue. Bringing tech-enabled innovations to patients through ecosystem partnerships.
We’re former founders, operators, and entrepreneurs. We’re MDs, PhDs, scientists, and technologists. We bring the know-how and networks of five full operating teams and deep expertise from across our consumer, enterprise, and fintech practices to help founders find their edge.
We win as one team, and we win big.
See Full Team
Sign up for our bio + health newsletter to get the latest take from us on the future of biology, technology, and care delivery.
